CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review

• by Sheng-Guang Li, Ruohan Yu, Lina Zhang, Jing Zhang, Yadan Zou, Ji Li, Ting Long, Yanfeng Zhang, Jing Pan

• July 1, 2026

Correction: Baseline neutrophil-to-lymphocyte ratio combined with SLEDAI predicts lupus low disease activity state at 1 year: a cohort study

• by Yadan Zou, Ruohan Yu, Kun Yang, Lina Zhang, Jing Zhang, Ji Li, Ting Long, Yanfeng Zhang, Sheng-Guang Li

• July 6, 2026

Distinct IgM and IgG autoantibody profiles characterize incomplete and classified systemic autoimmune diseases

• by Rebecca A. Wood, Neha Kodali, Nancy Redinger, A. Darise Farris, Christopher J. Lessard, R. Hal Scofield

• June 17, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min